Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Michigan Cancer Center |
---|---|
Information provided by: | University of Michigan Cancer Center |
ClinicalTrials.gov Identifier: | NCT00146029 |
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Condition |
---|
Metastatic Breast Cancer |
Study Type: | Observational |
Study Design: | Retrospective |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Michigan | |
University of Michigan Cancer Center | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | Anne F. Schott, M.D. | University of Michigan Cancer Center |
Study ID Numbers: | UMCC 3-27 |
Study First Received: | September 1, 2005 |
Last Updated: | March 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00146029 History of Changes |
Health Authority: | United States: Institutional Review Board |
Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer) |
Docetaxel Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site Skin Diseases Breast Neoplasms Breast Diseases |